

OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Xu-Jie Zhou

✉ zhouxujie@bjmu.edu.cn

Hong Zhang

✉ hongzh@bjmu.edu.cn

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 07 May 2023

ACCEPTED 30 May 2023

PUBLISHED 09 June 2023

CITATION

He J-W, Cui D-F, Zhou X-J, Chen P, Li Y, Zhang X, Wang Y-N, Gan T, Liu L-J, Shi S-F, Zhu L, Hou P, Lv J-C and Zhang H (2023) Corrigendum: Concurrent IgA nephropathy and membranous nephropathy, is it an overlap syndrome? *Front. Immunol.* 14:1218427. doi: 10.3389/fimmu.2023.1218427

COPYRIGHT

© 2023 He, Cui, Zhou, Chen, Li, Zhang, Wang, Gan, Liu, Shi, Zhu, Hou, Lv and Zhang. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Concurrent IgA nephropathy and membranous nephropathy, is it an overlap syndrome?

Jia-Wei He^{1†}, Dong-Feng Cui^{2†}, Xu-Jie Zhou^{1*}, Pei Chen¹, Yang Li¹, Xue Zhang¹, Yan-Na Wang¹, Ting Gan¹, Li-Jun Liu¹, Su-Fang Shi¹, Li Zhu¹, Ping Hou¹, Ji-Cheng Lv¹ and Hong Zhang^{1*}

¹Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China, ²Renal Division, The Third People's Hospital of Zhengzhou, Zhengzhou, China

KEYWORDS

IgA nephropathy, primary membranous nephropathy, galactose-deficient IgA1, anti-phospholipase A2 receptor, polygenic risk score

A corrigendum on

Concurrent IgA nephropathy and membranous nephropathy, is it an overlap syndrome?

by He J-W, Cui D-F, Zhou X-J, Chen P, Li Y, Zhang X, Wang Y-N, Gan T, Liu L-J, Shi S-F, Zhu L, Hou P, Lv J-C and Zhang H (2022) *Front. Immunol.* 13:846323. doi: 10.3389/fimmu.2022.846323

In the published article, there was an error in the legend for **Figure 5** as published. Part (A) incorrectly read “The comparison of the total-average proteinuria” instead of “The comparison of the time-average proteinuria”. The corrected legend appears below.

In the published article, there was also a word expression error.

A correction has been made to **Results, Follow-Up Evaluation**, paragraph number 4. This sentence previously stated:

“Compared to IgAN, the cumulative incidence of persistent proteinuria after therapy in patients with cIgAN/MN was lower than in IgAN ($P=0.001$).”

The corrected sentence appears below:

“Compared to IgAN, the cumulative incidence of persistent proteinuria after therapy in patients with cIgAN/MN was higher than in IgAN ($P=0.001$).”

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 5
(A) The comparison of the time-average proteinuria among patients with IgAN, clgAN/MN and MN. **(B)** Proteinuria persisted means patients could not achieve complete or partial proteinuria remission during follow-up, which were calculated according to the Kaplan-Meier method (log-rank test). ns, not significant.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.